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INTRODUCTION
The evolving covid-19 pandemic is placing unprecedent-
ed pressures on health systems. Many jurisdictions have 
cancelled or delayed elective surgical activity to spare 
precious hospital, critical care, and personal protective 
equipment resources; to increase system capacity; and 
to limit nosocomial spread of covid-191–4. This sudden 
scale-back in operative resources has led to re-triaging and 
prioritization of elective surgeries, including cancer cases. 
As covid-19 pressures on local resources mount, operative 
case categorization changes, and criteria become more 
stringent, resulting in a higher number of cancer surgeries 
potentially being deferred5.
Delays in cancer surgery could risk losing a window 
for resection, compromising curative-intent surgery, or 
delaying palliation, with impacts that can vary depending 
on the timing of the delay in the cancer care continuum. 
ABSTRACT
Objective We aimed to review data about delaying strategies for the management of hepatobiliary cancers requir-
ing surgery during the covid-19 pandemic.
Background Given the covid-19 pandemic, many jurisdictions, to spare resources, have limited access to operating 
rooms for elective surgical activity, including cancer, thus forcing deferral or cancellation of cancer surgeries. Surgery 
for hepatobiliary cancer is high-risk and particularly resource-intensive. Surgeons must critically appraise which 
patients will benefit most from surgery and which ones have other therapeutic options to delay surgery. Little guid-
ance is currently available about potential delaying strategies for hepatobiliary cancers when surgery is not possible.
Methods An international multidisciplinary panel reviewed the available literature to summarize data relating 
to standard-of-care surgical management and possible mitigating strategies to be used as a bridge to surgery for 
colorectal liver metastases, hepatocellular carcinoma, gallbladder cancer, intrahepatic cholangiocarcinoma, and 
hilar cholangiocarcinoma.
Results Outcomes of surgery during the covid-19 pandemic are reviewed. Resource requirements are summarized, 
including logistics and adverse effects profiles for hepatectomy and delaying strategies using systemic, percutane-
ous and radiation ablative, and liver embolic therapies. For each cancer type, the long-term oncologic outcomes of 
hepatectomy and the clinical tools that can be used to prognosticate for individual patients are detailed.
Conclusions There are a variety of delaying strategies to consider if availability of operating rooms decreases. 
This review summarizes available data to provide guidance about possible delaying strategies depending on patient, 
resource, institution, and systems factors. Multidisciplinary team discussions should be leveraged to consider 
patient- and tumour-specific information for each individual case.
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Furthermore, as hospital resources—including critical- 
care and specialized staff—become less available, periop-
erative outcomes could worsen. The ability to progress 
patients through the usual postoperative care pathways 
and to rescue potential complications could be comprom-
ised. In the mode of “safety first,” that compromised ability 
shifts the risk–benefit balance of surgery for individual pa-
tients and diseases, making changes to the usual decision- 
making and triaging for surgical cancer care inevitable 
and necessary.
Governing bodies and surgical societies have released 
statements about the need to delay and prioritize elective 
surgeries, including those for cancer5,6. However, those 
high-level statements lack either detailed disease- and 
patient-specific guidance or the data and resource infor-
mation to support decision-making (Table i)7–9.
The logistics of care and operating room availability 
can shift quickly as the pandemic evolves, and surgical 
decisions have to rapidly adapt. Multiple factors to consider 
for each case include not just the usual disease and patient 
factors (chance for cure or further spread of the cancer, risk 
for complications), but also, particularly in the pandemic, 
hospital resource use [for example, the need for an intensive 
care unit (icu) stay], the likelihood of prolonged hospital-
ization, and risk of exposure to and outcomes of covid-19. 
Weighing all those considerations requires an understand-
ing of expectations with standard-of-care surgery, available 
mitigating or delaying strategies and their outcomes, and 
the risks posed by covid-19 infection.
The aim of the present review was to provide detailed 
information to support decision-making for the surgical 
management of hepatobiliary cancers that can be adapt-
ed to rapidly evolving situations and surgical resource 
availability. Rather than developing guidelines or recom-
mendations that could quickly become obsolete, we aimed 
to summarize within a single review the data to support 
difficult discussions and decisions. We focus on surgically 
treatable intrahepatic malignancies and endorse the logis-
tics of operating room workflow and protocols during the 
pandemic that have previously been outlined3,10,11.
METHODS
A non-systematic search was conducted of the literature (as 
of 10 April 2020), surgical and oncology society guidelines, 
and expert statements about the management of the most 
common hepatobiliary malignancies in surgical oncology 
practice:
 n Colorectal liver metastases (crlms)
 n Hepatocellular carcinoma (hcc)
 n Gallbladder carcinoma (gbc)
 n Intrahepatic cholangiocarcinoma (icc)
 n Hilar cholangiocarcinoma
Relevant data about standard-of-care surgical man-
agement and possible mitigating strategies to be used 
as a bridge to surgery were extracted and summarized. 
The components of care summarized for each treatment 
strategy were: short-term outcomes (morbidity and mor-
tality), long-term oncologic outcomes (survival), factors 
influencing and tools predicting outcomes, and resource 
requirements for therapy delivery. When available, we 
also abstracted data about patient outcomes with delays 
in surgery.
The search and data abstraction were performed by 
2 authors (SB, JH), with subsequent review by a multi-
disciplinary (surgical, medical, and radiation oncology), 
international (North America, Australasia, and Europe) 
group of oncologists to ensure applicability within vari-
ous health systems and in countries at different phases of 
the current pandemic. No formal consensus criteria were 
applied to the review.
RESULTS
Risk of COVID-19 for the Surgical Oncology Patient
Data about outcomes of covid-19–infected cancer patients 
are limited, particularly with respect to surgical oncology. 
Repeated visits to the hospital, risk from social and noso-
comial contacts, and the immunosuppressive effects of 
surgical stress could contribute to a higher risk of develop-
ing covid-19 for patients with cancer12,13. However, that risk 
is highly confounded by the prevalence of asymptomatic 
covid-19 in the community and the lag between infection 
and symptoms. Information about vulnerability to covid-19 
can guide decision-making for surgical cancer patients. 
Comorbidities associated with higher risk from covid-19 
(for example, hypertension, diabetes, pulmonary disease, 
cardiovascular disease) and age could be used to arrive at 
the most optimal risk–benefit balance14.
Two major epidemiologic studies from China drew 
data from 18 and 10 cancer patients infected with covid-19 
and suggested a higher rate of icu admission, need for 
ventilation, and death (39%) in that patient population 
compared with the general population (8%)12,13. The case 
fatality rate for all cancer patients with covid-19 infection 
is reported to be higher than the overall case fatality rate 
(5.6% vs. 2.3%), although no details are available about that 
subpopulation15. However, most Chinese patients with can-
cer and covid-19 in those series were 4 years or more from 
their initial cancer diagnosis, and only 1 had undergone 
surgery and 3 had received chemotherapy within a month 
of covid-19 infection12. A Chinese series of hospitalized 
patients with covid-19 that included 105 patients with and 
233 without cancer observed that patients with cancer ex-
perienced higher rates of severe events of icu admission, 
mechanical ventilation, and death16. After adjusting for age, 
sex, and comorbidities, cancer was not independently asso-
ciated with increased odds of icu admission (odds ratio: 1.5; 
95% confidence interval: 0.70 to 3.1) or death (odds ratio: 
2.2; 95% confidence interval: 0.46 to 5.2). Overall, those data 
cannot definitively support the idea that delaying therapy 
would protect from covid-19 infection. However, covid-19 
infection manifesting during the postoperative period 
is associated with poor outcomes. An early publication 
described 34 patients who were operated on while incu-
bating covid-19 that manifested clinically after surgery; all 
developed pneumonia, 44% required icu admission, and 
20% died17. A large multicentre cohort study at 235 hospi-
tals in 24 countries included 1128 patients who underwent 
any operation and were diagnosed with covid-19 within a 
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TABLE I Summary of statements from major surgical and oncology societies about cancer surgery and hepatobiliary malignancy during the 
COVID-19 pandemic
Society Statement
American Society of Clinical Oncology
• Individual determinations about the need for cancer surgery based on potential harms of delaying surgery, including consideration of the 
need for postoperative ICU care.
• Reasonable to consider neoadjuvant therapy or delay in surgery in situations in which neoadjuvant therapy is available, but not 
routinely considered:
§	Weigh risks of delay in surgery against burden on hospital resources and patient risk of exposure to COVID-19, and
§	consider risks of exposure to COVID-19 and of immunosuppression with chemotherapy.
• No evidence that immunosuppressive therapy should be delayed or held. Individual risk assessment required.
Hepatobiliary cancers specifically: links to statement from Society of Surgical Oncology
For details: https://www.asco.org/asco-coronavirus-information
National Comprehensive Cancer Network
• Cancer surgery is not considered elective, but requires prioritization.
• Shared decision-making optimized with surgeon-to-patient discussions (telephone calls).
Hepatobiliary cancers specifically: no statement
For details: https://www.nccn.org/covid-19/
American College of Surgeons
• Patients should receive appropriate and timely surgical care, including operative management, based on sound surgical judgment and 
availability of resources.
• Virtual multidisciplinary discussions for triage of cases based on local resources, COVID-19 prevalence, and alternative nonsurgical 
therapies.
Three phases guide decision-making relative to level of the pandemic:
• Semi-urgent setting – preparation phase
• Urgent setting
• Local resource scarcity
Hepatobiliary cancers specifically: For oligometastatic colorectal cancer, use effective systemic therapy, if available. No statement for 
hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and gallbladder cancer.
For details: https://www.facs.org/covid-19/clinical-guidance/elective-case
Society of Surgical Oncology
Follows the American College of Surgeons phases of the pandemic.
Hepatobiliary cancers specifically:
Phase 1 – Semi-urgent setting
Procedures to be done:
• Intrahepatic cholangiocarcinoma 
(symptoms or not)
• Colorectal liver metastases finishing 
neoadjuvant therapy in which further 
chemotherapy would be detrimental 
to liver function
Consider alternative therapies:
• Large intrahepatic cholangiocarcinoma 
requiring major hepatecomy – 
chemotherapy
• Hepatocellular carcinoma – ablation or 
liver-directed therapies
• Incidental gallbladder cancer requiring 
staging or re-resection – delay
Phase 2 – Urgent setting
Procedures to be done:
• Advanced tumour at risk of becoming 
unresectable with delay
• Management of complications if 
interventional approach not feasible
• Bleeding tumours that cannot be  
managed with interventional radiology, 
radiation, or endoscopy
Consider alternative strategies:
• Chemotherapy upfront for tumours in 
which it is not routine, if can be done 
safely
• Radiation therapy upfront for tumours 
in which it is not routine, if can be 
done safely
• SBRT for liver metastasis
• Liver-directed therapy as bridge to surgery
Phase 3 – Local resource scarcity
Procedures to be done:
• Management of complications if 
interventional approach not feasible
• Bleeding tumours that cannot be  
managed with interventional radiology, 
radiation, or endoscopy
Alternative strategies:
• Same as Phase 2
For details: https://www.surgonc.org/resources/covid-19-resources/
European Society of Surgical Oncology
Liaise with colleagues regarding feasibility and practicality of chemotherapy, radiation therapy, and targeted treatment to reduce impact 
on hospital beds for surgery, and decision on case-by-case basis.
Hepatobiliary cancers specifically: no statement
For details: https://www.essoweb.org/news/esso-statement-covid-19/
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window of 7 days preoperatively to 30 days postoperative-
ly18. The overall 30-day mortality rate was 23.8%, and the 
rate of pulmonary complications was 51.2%.
Standard of Care and Role of the 
Multidisciplinary Team
Despite the limitations imposed by the covid-19 pandemic, 
surgeons should strive to provide standard-of-care therapy. 
All treatment decisions, particularly those in which stan-
dard therapy has to be altered or delayed, must be made in a 
multidisciplinary team. Given that access to chemotherapy 
and radiation therapies might also be restricted, ongoing 
communication with oncology colleagues is essential. 
Treatment options, risks and benefits, and the perceived 
outcome of each intervention have to be discussed with 
the patient to arrive at the situational best solution and at 
informed consent with the patient. Notably, patients and 
surgeons will have different personalities, values, and ex-
pectations, all of which could affect choice of treatment. 
However, opting for risk-averse pathways might also be jus-
tified for the common good in a situation in which resources 
and access to intensive care support might be restricted.
Therapeutic Options and Resource Use
Table ii summarizes general resource use for possible 
treatment strategies, to be interpreted in light of specif-
ic institutional care processes and resource availability 
before, during, and after the pandemic.
Hepatectomies are a heterogeneous group of proced-
ures, ranging from laparoscopic wedge resection of a single 
segment to trisegmentectomy with bile duct resection and 
reconstruction19. Patients at highest risk of morbidity and 
mortality after hepatectomy are those with comorbidi-
ties, an age of 75 years or greater, or underlying cirrhosis; 
those undergoing major liver resection (≥4 liver segments), 
synchronous colorectal and liver resection, and biliary 
reconstruction; and those needing blood transfusions19–21. 
The risk of requiring care in an icu after surgery is higher 
for patients undergoing major hepatectomy and those re-
ceiving blood transfusions22. For patients with minor liver 
disease, a laparoscopic approach can be beneficial, with 
lower morbidity and a shorter hospital stay19.
The risk of morbidity and mortality can be predicted 
using the National Surgical Quality Improvement Program 
developed by the American College of Surgeons based on 
multi-institutional prospectively validated data23. Blood 
transfusion is another important marker of postoperative 
morbidity and higher use of resources after hepatectomy, 
and can be estimated using the validated transfusion risk 
score based on data about preoperative anemia, back-
ground liver disease, and extent of planned hepatecto-
my24,25. Transfusion is especially important to consider, 
given that the covid-19 pandemic can lead to allogeneic 
blood shortages as a result of physical distancing and 
confinement policies26.
Chemotherapy is delivered in an outpatient setting. It 
involves repeated visits to cancer clinics, with associated 
risks related to social exposure because of travel, waiting 
room crowding, and sequential use of a chemotherapy 
chair that could increase the risk of exposure to covid-19 
infection. Moreover, chemotherapy means exposure to 
agents that might compromise the quality of the liver rem-
nant and create a risk of immunosuppression27.
Percutaneous ablation, such as radiofrequency abla-




Follows the American College of Surgeons phases of the pandemic.
Hepatobiliary cancers specifically:
• Consider patient comorbidities and age to assess relative risks and benefits with potential exposure to COVID-19 compared with 
alternative treatment options.
• Consider changes in resources available at various stages of the pandemic.
• For patients facing a potentially prolonged hospital stay or at higher risk for complications requiring ICU management, surgery should be 
timed to available resources.
Phase 1 – Semi-urgent setting
• Hepatocellular carcinoma – hepatectomy, 
transplant, ablation
• Colorectal liver metastases – hepatectomy 
for intermediate-acuity surgery and 
healthy patient, chemotherapy for 
intermediate-acuity surgery and 
unhealthy patient
• Intrahepatic cholangiocarcinoma – 
hepatectomy for intermediate-acuity 
surgery and healthy patient, chemotherapy 
for intermediate-acuity surgery and 
unhealthy patient
• Hilar cholangiocarcinoma – resection or 
transplantation as indicated
Phase 2 – Urgent setting | Phase 3 – Local resources scarcity
• Hepatocellular carcinoma – delay definitive therapy; TACE ablation or observation
• Colorectal liver metastases – chemotherapy
• Intrahepatic cholangiocarcinoma – chemotherapy or embolic therapy
• Hilar cholangiocarcinoma – chemotherapy, chemoradiation, or transfer to a facility with 
more resources
For details: https://www.sages.org/sages-ahpba-recommendations-surgical-management-of-hpb-cancer-covid-19/
ICU = intensive care unit; SBRT = stereotactic body radiation therapy; TACE = transarterial chemoembolization.
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suites or in the operating room, depending on the insti-
tution. Grade 3 adverse events in percutaneous ablation 
occur in 4%–5% of patients28. Ablative radiation therapy 
[stereotactic body radiation therapy (sbrt)] is an outpatient 
procedure in radiation therapy facilities. The adverse ef-
fects profile of sbrt is minimal, with a 6%–7% risk of grade 3 
gastrointestinal toxicity29,30.
Finally, liver embolization is typically performed in 
the radiology suite or in the operating room, as an outpa-
tient or inpatient procedure, depending on the institution. 
Post-embolization syndrome—with fever, abdominal pain, 
and elevated transaminases—is the most frequent compli-
cation31. For transarterial chemoembolization (tace, using 
drug-eluting beads containing irinotecan) in patients with 
crlms, 15%–30% experience either pain, vomiting, fatigue, 
or fever, with most adverse events being grade 232,33. For 
tace in patients with hcc, most adverse effects are also 
grade 2. Across studies, 20%–30% of patients experience 
either pain, fever, nausea, or fatigue, and 5%–30% can de-
velop ascites depending on liver function31.
Colorectal Liver Metastases
Hepatectomy and Oncologic Outcomes
The 5-year overall survival (os) for patients with resectable 
crlms (liver only) can reach 60%, with a median os of 74 
months after curative-intent surgery34,35. In a retrospect-
ive series of patients with fewer than 4 metachronous 
metastases treated between 2000 and 2010, longer time 
from diagnosis to crlm resection was associated with worse 
os36. Median os was 76 months in patients who underwent 
surgery within 3 months of diagnosis, compared with 58 
months for those whose surgery occurred later, adjusted 
for preoperative receipt of chemotherapy.
Systemic Therapy
Median survival with systemic therapy alone for unresect-
able crlms has been reported to be 22 months for patients 
who do not achieve conversion to resectability37; other 
series have reported durations up to 40 months38. The 
availability of effective systemic therapies has led to an 
increased use of neoadjuvant chemotherapy. In patients 
with resectable liver metastases (low disease burden), 
upfront surgery is often favoured. However, for patients 
with larger lesions or borderline resectable disease, neo-
adjuvant chemotherapy is the preferred approach. In the 
neoadjuvant setting, chemotherapy can be used to assess 
disease biology and patient selection, with potential benefit 
in recurrence-free survival, but no proven gain in os39,40.
Recent guidance from the American College of Sur-
geons (24 March 2020) recommends that surgery be de-
layed for patients with oligometastatic colorectal cancer 
for which effective systemic therapy is available41. If case 
prioritization requires a delay in resection of crlms, ad-
ministration of chemotherapy before resection would be 
reasonable. For patients who are finishing pre-hepatectomy 
chemotherapy initiated before an operating room resource 
restriction, consideration can be given to continuing with 
further cycles depending on patient tolerance and the 
balance between risk of hepatotoxicity from chemothera-
py (given the expected future liver remnant) and the risk 
for disappearing metastases that will complicate future 
curative-intent resection.
Ablation
Data about the outcomes of percutaneous ablation come 
from cohorts of patients with unresectable crlms. In a 
phase ii randomized trial involving 119 patients with 
TABLE II Safety profile and resource use for treatment strategies










Hepatectomy Major morbidity: 20% 
Mortality: 2%
Inpatient 3–6 Days 5%–10% Yes Relative: 
postoperative 
SIRS
Systemic therapy Depends on regimen. 
Consider neutropenia 
and lymphopenia.











6%–7% Grade 3 
gastrointestinal events 
(if proximity to  
duodenum or stomach)





Outpatient 1 Day 






a Excludes routine planned postoperative admissions for monitoring.
b That is, mask, gown, gloves—PPE requirements for usual care (could vary during COVID-19 pandemic, depending on institutional protocols).
ICU = intensive care unit; PPE = personal protective equipment; SIRS = systemic inflammatory response syndrome; OR = operating room; SBRT = 
stereotactic body radiation therapy.
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unresectable, liver-only crlms, better median os was ob-
served for rfa combined with systemic therapy (45.6 months) 
than for systemic therapy alone (40.5 months)38. In retro-
spective studies of resectable disease, risk of local recurrence 
is higher and os is lower with ablative techniques than with 
resection42–44. Local recurrence and 5-year os after ablation 
are reported at 37% and 27% respectively for isolated crlms42. 
As evidenced by an ongoing randomized noninferiority trial 
comparing hepatectomy with ablation for resectable liver 
metastases, percutaneous ablation is considered by some 
to be a potential curative option for crlms45.
Retrospective series of patients with unresectable liver 
metastases treated with sbrt have shown promising disease 
control. Local control rates at 2 years range from 57% to 
100% in patients with poor prognosis and unresectable 
disease46. In a phase ii trial comparing sbrt plus chemo-
therapy with chemotherapy alone for oligometastases 
(13% liver), median os was prolonged at 41 months for the 
sbrt regimen compared with 28 months for chemotherapy 
alone. Compared with percutaneous ablation, sbrt can 
treat larger lesions, but might be limited for crlms localized 
near the stomach or duodenum29,30. Treatment intent with 
sbrt is not curative; if used as a mitigating strategy, liver 
resection would subsequently be required. Surgery after 
sbrt is feasible, although not well described47.
If there is no access to the operating room or if pursuing 
chemotherapy is not possible (or both), ablation could be 
a delaying strategy to ensure local control while awaiting 
surgery. Curative-intent treatment requires subsequent 
resection of the ablated lesion when operating resources 
are available. The choice for ablation also depends on its 
technical limitations (tumour size, number, and localiza-
tion) and required resources depending on institutional 
protocols (inpatient vs. outpatient care; operating room).
TACE
Another approach for patients with unresectable or medic-
ally inoperable disease is tace, with a goal of local control 
and improved os. No prospective comparison of tace with 
resection has been conducted. In the unresectable setting, 
tace using drug-eluting beads containing irinotecan has 
an overall radiologic response rate between 60% and 80%, 
and a median os ranging from 14 to 25 months33,48.
Clinical Risk Tools
Multiple patient and disease factors influence oncologic 
outcomes after hepatectomy for crlms; clinical risk tools 
can assist in estimating outcomes if necessary for decision- 
making49. The most common tool is the Clinical Risk 
Score50,51. Rated from 0 to 5, the Clinical Risk Score assigns 
1 point for each of these factors: node-positive primary 
tumour, liver metastases larger than 5 cm, more than 1 
lesion, serum carcinoembryonic antigen greater than 
200 ng/mL, and a disease-free interval less than 12 months. 
A score of 0 corresponds to a 5-year os of 60%, and a score 
of 5, to a 5-year os of 14%. The Genetic and Morphological 
Evaluation score is a more recent tool that incorporates 
molecular information and has better discrimination than 
the Clinical Risk Score52. Six preoperative factors produce a 
total score in the range 0–7: KRAS mutation (1 point), serum 
carcinoembryonic antigen greater than 20 ng/mL (1 point), 
node-positive primary tumour (1 point), tumour burden 
score in the 3–8 range (1 point) or 9 and higher (2 points), 
and extrahepatic disease (2 points). The 5-year os estimate 
is 73.4% for patients at low risk (score: 0–1), 50.6% for those 
at medium risk (score: 2–3), and 11% for those at high risk 
(score: ≥4).
Hepatocellular Carcinoma
Hepatectomy and Oncologic Outcomes
Patients with Barcelona Clinic Liver Cancer (bclc) stage 0 or A 
hcc are considered for hepatectomy, with some surgeons 
considering resection for those with bclc B disease53,54. 
With hepatectomy, these are the estimates for 5-year os55:
 n for bclc 0: 86%.
 n for bclc A with 1 lesion of 2–5 cm or 2–3 lesions less 
than 3 cm: 69%.
 n for bclc A with 1 lesion of 5 cm or larger: 57%.
 n for bclc B with 2–3 lesions of 3 cm or larger, or with 4 
or more lesions: 50%.
In the present review, we focus on patients who are 
candidates for resection and who might be delayed or repri-
oritized during the pandemic. Liver transplantation also 
plays a crucial role in the management of hcc. Transplan-
tation presents unique considerations related to operating 
room resource availability, changes in the donor pool, risk 
for living donors, and risk of infection and transmission of 
covid-19, which are beyond the scope of the present review 
and have been summarized elsewhere56–58. Any considera-
tion of strategies meant to mitigate operating room delays 
for resection of hcc should include the understanding that 
access to transplantation might still be compromised after 
the pandemic, such that delaying strategies should not rely 
on availability of salvage transplantation.
Ablation
Radiofrequency ablation is associated with local recur-
rence rates of 0.9%, 1.4%, and 25% for hccs of less than 
2 cm, less than 3 cm, and 3–5 cm respectively59,60. Although 
no difference in os has been observed with liver resection 
or rfa for hccs less than 5 cm in randomized controlled 
trials, the local recurrence rate is higher with rfa (5-year 
recurrence-free survival: 51.3% vs. 28.7%; hazard ratio: 
0.56; 95% confidence interval: 0.40 to 0.78)61. If ablation 
is used without subsequent resection, and if the tumour 
recurs, patients can be candidates for salvage resection 
or salvage transplantation with outcomes similar to those 
with upfront transplantation62.
The sbrt modality is used for unresectable hcc, but 
has not been prospectively compared with resection. 
Prospective series have demonstrated local control rates 
between 80% and 100% at 1–3 years63–65. The ability to 
safely deliver sbrt is restricted by the underlying liver 
function, with a Child–Pugh score of 8 or greater being a 
relative contraindication66. The modality can be a bridge 
to liver transplantation comparable to both tace and rfa67.
TACE
Outcomes of tace have been reported mostly for unre-
sectable hcc, with the 5-year os being 30%68. Literature 
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about neoadjuvant tace for hcc reported no difference in 
os between tace followed by hepatectomy and hepatecto-
my alone in higher-risk hcc69. If tace is used as a strategy 
to delay surgery, resection should eventually follow so as 
not to compromise os. Although operating time is long-
er after tace, postoperative morbidity and mortality are 
unchanged69,70.
Systemic Therapy
Sorafenib and lenvatinib are used for advanced and un-
resectable hcc, with a median os of 12–13 months being 
reported in the reflect trial71–73. The emergence of new 
data showing responses to lenvatinib as evidenced by 
the Response Evaluation Criteria in Solid Tumors could 
herald the use of systemic therapy to downstage or delay 
surgery until optimal conditions are achieved in patients 
who might not be eligible for other delaying strategies as 
described earlier.
Clinical Risk Tools
A variety of scoring tools are available to assess outcomes 
of liver transplantation for hcc, but fewer are available for 
hepatectomy. A risk score developed using the Surveillance, 
Epidemiology, and End Results program database incor-
porates sex, tumour size, number of tumours, presence 
of bilobar disease, and major vascular invasion to predict 
os, but has not been externally validated74. The predicted 
5-year os is 69% with a low-risk score, 51% with a medium- 
risk score, and 19% with a high-risk score.
Gallbladder Cancer
Hepatectomy and Oncologic Outcomes
Gallbladder cancer amenable to resection most often 
presents incidentally after simple cholecystectomy75,76. 
After a negative metastatic work-up, indications for radical 
re-resection include T1b or higher node-positive disease 
or a positive cystic duct margin77. Resected localized gbc 
(stages I–II) typically has a 5-year os of 50%–60%78,79. Com-
pared with simple cholecystectomy, radical resection with 
extended cholecystectomy is associated with improved 
os for T2 and higher disease78. In T1b tumours, radical 
resection has been associated with a decrease in the risk of 
local recurrence without improvement in os80. Major liver 
resection, including multivisceral resection, is advocated 
by some for os benefit, but in the setting of the pandemic, 
the associated increased risks of major morbidity, pro-
longed icu stay, and mortality should be carefully weighed 
against that benefit81,82. Finally, it should be mentioned 
that the extent of hepatectomy and lymph node dissection 
is debated and heterogeneous between studies, and that 
available data are biased by selection of fitter patients for 
extended resection83–86.
Delaying Strategies
For incidental gbc eligible for radical re-resection, delay-
ing strategies can include observation with short-term 
re-imaging or chemotherapy76. Use of chemotherapy is 
contingent on the availability of an effective regimen for 
gbc, which can be appreciated based on data from the ad-
juvant setting. Although the bilcap trial’s intention-to-treat 
analysis was negative for its primary endpoint, the trial 
(which included all biliary tract cancers) indicated favour-
able os with 8 cycles (24 weeks) of capecitabine as adjuvant 
therapy in the per-protocol population (which excluded 
ineligible patients and patients failing to complete at 
least 1 cycle of capecitabine)87. Although statistical sig-
nificance was not reached in bilcap’s intention-to-treat 
population, a survival benefit of several months for those 
patients with usually dismal outcomes can be considered 
clinically meaningful. Therefore, when tumour control is 
needed while surgery is delayed, chemotherapy could be 
considered88. While not supported with data, preoperative 
chemotherapy appears ethically acceptable given that it is 
currently the subject of a randomized controlled trial89 and 
has been introduced as routine in some centres90.
Clinical Risk Tools
Clinical tools for gbc detected incidentally after cholecys-
tectomy or diagnosed on imaging are few, were developed 
on small cohorts, are not well validated, and include infor-
mation available only after surgery91–93. One scoring system 
focused on preoperative factors, but included both surgical 
and nonsurgical (metastatic) cases94. That system uses age, 
Eastern Cooperative Oncology Group performance status, 
serum alkaline phosphatase, tumour size, and presence of 
metastasis to create a score from 0 to 30 to predict os. In 
surgical cases, median survival is 37 months for scores of 
0–21.9, 30 months for scores of 22–25.9, 15 months for scores 
of 26–29.9, and 8 months for a score of 30.
Intrahepatic Cholangiocarcinoma
Hepatectomy
The typical curative-intent management of icc is hepatec-
tomy, with a 5-year os of 30%95. Postoperative mortality 
of 7.6% after hepatectomy for primary liver tumours is 
considerably higher than the rate typically cited for all 
hepatectomies19.
Systemic Therapy
Retrospective cohort studies have reported on neoadjuvant 
chemotherapy for initially unresectable icc. Of 74 patients 
with locally advanced unresectable disease receiving 
various chemotherapy regimens (59% being doublet 
gemcitabine–oxaliplatin), 39 were converted to resect-
ability (53%) after a median of 6 cycles96. Median os after 
resection in that group was 24 months, compared with 
26 months in initially resectable icc.
Ablation
Ablative therapies appear to be effective in icc, although 
experience is limited. A meta-analysis of rfa reported 
local tumour progression in 21% of patients and a 5-year 
os of 25%97. A small series of sbrt observed a median os of 
22 months with a 1-year local control rate of 78%98.
TACE
Radioembolization with 90Y and tace have both been 
used for unresectable icc. Median os was similar for 
the combination of drug-eluting beads containing 
irinotecan plus chemotherapy and for chemotherapy 
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(gemcitabine–oxaliplatin) alone, at 12 and 11 months 
respectively; median os with conventional tace was 
6 months99. In a meta-analysis, 90Y radioembolization 
was associated with a median os of 15 months100.
Clinical Risk Tools
Various prognostic tools have been described for icc, but 
none are universally accepted101. Few tools incorporate 
patient characteristics such as age and sex, and most rely on 
pathology variables that might not be available before sur-
gery102–104. Recently, the LabScore combined carbohydrate 
antigen 19-9, neutrophil-to-lymphocyte ratio, platelets, 
and albumin into a published formula to predict 5-year os 
after resection as 55% for a score of 0–9, 38% for a score of 
10–19, and 22% for a score of 20 or more105.
Hilar Cholangiocarcinoma
Hepatectomy and Oncologic Outcomes
For the few resectable hilar cholangiocarcinomas that are 
amenable to curative-intent treatment, the 5-year os is 
8.4% in node-positive disease and 25.9% in node-negative 
disease106. Given the extent and complexity of hepatecto-
my, and the need for a biliary–enteric anastomosis, major 
morbidity and mortality are higher in these patients107.
Chemoradiation
Conversion from unresectable to resectable hilar cholan-
giocarcinoma has been reported with chemoradiation (11 
of 15 patients at a single institution)108. For resectable or 
borderline resectable disease, single-centre experiences 
with neoadjuvant chemoradiation for mixed cohorts of 
hilar and extrahepatic cholangiocarcinoma have report-
ed 90%–100% R0 resection rates and 25%–33% complete 
pathologic responses109,110. Thus, tumour control appears 
achievable with preoperative chemoradiation if surgery has 
to be delayed. Finally, for the select few patients with tech-
nically unresectable hilar cholangiocarcinoma who might 
be considered for transplantation, neoadjuvant chemora-
diation offers benefits in selection and prognosis111.
SUMMARY
The covid-19 pandemic affects many treatment decisions 
for patients with and without the virus. Reduced access 
to the operating room and lessened availability of critical 
care services for postoperative management could force 
the use of treatment strategies outside the standard of care 
to delay surgery. A variety of delaying strategies could be 
considered if operating room availability decreases. All 
strategies have pros and cons for patients and health sys-
tems that should be weighed. The quality and availability 
of data are variable. Evidence comparing typical curative- 
intent surgery with delaying options is rarely available. In 
the present review, we summarized the available data to 
provide some guidance with respect to possible delaying 
strategies depending on patient, resource, institution, and 
systems factors. Multidisciplinary team discussions should 
be leveraged to consider patient- and tumour-specific 
information to make the best possible decision for each 
individual case. Finally, it is important to emphasize that 
the nonsurgical therapies discussed should be used only 
with the goal of maintaining tumour control while await-
ing hepatectomy. Curative-intent resection remains the 
cornerstone of therapy and the ultimate goal.
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